Royalty Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Royalty Pharma's estimated annual revenue is currently $2.3B per year.
- Royalty Pharma's estimated revenue per employee is $30,945,946
- Royalty Pharma's total funding is $834.1M.
Employee Data
- Royalty Pharma has 74 Employees.
- Royalty Pharma grew their employee count by 16% last year.
Royalty Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder & CEO | Reveal Email/Phone |
2 | VP | Reveal Email/Phone |
3 | Chief Accounting Officer | Reveal Email/Phone |
4 | VP | Reveal Email/Phone |
5 | Investor Relations & Corporate Communications, VP | Reveal Email/Phone |
6 | VP | Reveal Email/Phone |
7 | Chief Technology Officer | Reveal Email/Phone |
8 | VP, Investments & Deputy General Counsel | Reveal Email/Phone |
9 | SVP Strategy and Analytics | Reveal Email/Phone |
10 | VP, Investments and Deputy General Counsel | Reveal Email/Phone |
Royalty Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Royalty Pharma?
Royalty Pharma is the industry leader in acquiring revenue-producing intellectual property -- principally royalty interests in marketed and late stage biopharmaceutical products with approximately $5 billion in assets. Royalty Pharma currently owns a diversified portfolio of royalty interests in several high-quality blockbuster biopharmaceutical products, including Abbott's Humira(R), J&J/Centocor's Remicade(R), Pfizer's Lyrica(R), Amgen's Neupogen(R) and Neulasta(R), Genentech's Rituxan(R), Gilead's Emtriva(R), Truvada(R) and Atripla(R), and Celgene's Thalomid(R).
keywords:N/A
$834.1M
Total Funding
74
Number of Employees
$2.3B
Revenue (est)
16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Royalty Pharma News
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the...
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the...
Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica,...
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast a ...
NEW YORK, NY - Royalty Pharma plc (Nasdaq: RPRX) announced that it will participate in the following upcoming investor conferences during the month of September: Citi's 16th Annual BioPharma Virtual Conference on Thursday, September 9 at 10:40 a.m. EDT Morgan Stanley's 19th Annual Global Healt ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $16.7M | 74 | -14% | N/A |
#2 | $16.7M | 74 | -7% | N/A |
#3 | $9M | 74 | 17% | $12.4M |
#4 | $15.2M | 74 | 7% | N/A |
#5 | $10M | 74 | -7% | N/A |